Investigation of Cytotoxic Effect of a Benzimidazole Derivative in DLD-1 Cell Line Using MTT Cell Viability Test and Histopathological Parameter Methods

INTRODUCTION: A class of traditional chemotherapy medications with a wide range of pharmacological activity is benzoimidazole. Imidazole compounds show anticancer activity both in vitro and in vivo, according to recent literature publications. Making a benzimidazole derivative and testing its anticancer properties in DLD-1 colon cancer cells was the study's goal.
METHODS: Hematoxylin eosin staining, caspase-3 activity, and the MTT assay were among the biological investigations.
RESULTS: A microplate reader was used to measure the impact of SL-9 on cell density in light of the MTT analysis data, and a logarithmic slope line was produced. The IC50 value of SL-9 was found to be 57.68 µM based on the logarithmic slope line. Over the course of treatment with 20 μM SL-9, a notable decline in cell viability was noted. Typical apoptotic alterations, particularly nuclear condensation and nuclear fragmentation, were noted in the cells with morphological parameters 24 hours after the start of treatment. These results imply that SL-9 caused cell death by apoptosis. When measured in terms of mitotic activity, the control group showed higher levels of mitotic activity than the treatment group.
DISCUSSION AND CONCLUSION: Therefore, it was discovered that the substance SL-9, a benzimidazole derivative, had a strong lethal impact when administered to colon cancer cells at varying concentrations. More thorough research should examine these beneficial effects of SL-9 treatment on colon cancer cells from a variety of angles.